Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

How can we improve access to new (and old) antibiotics in Australia?

- Featured Image

It is hoped that new registration mechanisms and economic incentives will encourage much-needed drug development

That there is a problem with antibiotic resistance is no surprise to clinicians who deal with antibiotic-resistant organisms in day-to-day practice. Scenarios increasingly being faced include health care-associated infections (particularly those acquired overseas) where few therapeutic options are available, bacteraemia following transrectal prostate biopsy, simple urinary tract infections for which no oral antibiotics are effective, and drug-resistant gonorrhoea, tuberculosis and typhoid fever. The inexorable rise in antibiotic resistance coincides with a dwindling pipeline of novel antimicrobial agents under development.1,2 A recent review identified only two new antibiotics registered in the United States since 2009 (of which only one is currently available in Australia) and only seven antibiotics active against gram-negative bacteria in clinical development.3 Only four multinational pharmaceutical companies were engaged in the development of antibacterials; barriers to development and registration of new antibiotics were noted (including the need for large efficacy and…

email